Vitrakvi® (larotrectinib) for NTRK Gene Fusion–Positive Tumors

What Vitrakvi® Is and How It Works

Vitrakvi® (larotrectinib) is an oral targeted cancer medicine for adults and children. It treats solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. The fusion drives cancer growth. Larotrectinib binds TRKA, TRKB, and TRKC proteins and stops their signaling. Tumor cells that depend on these signals can shrink or stop growing.

If you are comparing Vitrakvi price or plan to buy vitrackvi online, this page explains the medication, dosing, safety, and how to order. Youdrugstore is a licensed Canadian pharmacy headquartered in Manitoba; prescriptions are reviewed by licensed pharmacists before dispensing, and you can order online at Canadian prices with support during posted chat hours.

Vitrakvi is available as capsules and an oral solution. The usual adult dose is 100 mg taken twice daily. Pediatric dosing is based on body surface area. Treatment continues until disease progression or unacceptable side effects. The Vitrakvi label covers use in patients whose tumors are metastatic or surgery would cause severe harm, and who have no satisfactory alternative treatments. Bayer is the Vitrakvi manufacturer, and bayer vitrackvi materials provide detailed guidance for prescribers.

Regulatory history supports its broad, tumor‑agnostic role. Vitrakvi FDA approval followed compelling response rates across multiple tumor types. The initial larotrectinib FDA approval was in 2018, and approvals have since expanded. EMA authorization and Health Canada listings are also in place.

Dosage and Usage

• Adults: 100 mg orally twice daily, with or without food, until disease progression or unacceptable toxicity.
• Pediatrics: 100 mg/m² orally twice daily (maximum 100 mg per dose). Use the oral solution when needed to match weight or body surface area.
• Capsules: swallow whole; do not open or crush. Solution: measure with the provided oral syringe to ensure accurate dosing.
• Timing: take doses about 12 hours apart. If vomiting occurs after a dose, do not take an extra dose; take the next dose as scheduled.
• Missed dose: take it as soon as remembered unless the next dose is due within 6 hours; then skip the missed dose and resume the regular schedule.
• Drug interactions: strong CYP3A inhibitors or inducers can change exposure. Prescribers may avoid strong inducers and reduce the larotrectinib dose when strong inhibitors are necessary.
• Driving or tasks needing alertness: dizziness and fatigue can occur; use caution.
• Common strengths: search terms like vitrackvi 100mg often refer to Vitrakvi 100 mg capsules.

• Store capsules and solution at 20–25 °C (68–77 °F); excursions 15–30 °C (59–86 °F) are allowed.
• Keep the oral solution in the original bottle; discard 90 days after first opening. Do not freeze.
• Protect from excessive heat, moisture, and light. Keep out of reach of children.
• For travel, carry your medication in hand luggage with the pharmacy label attached.
• Use a travel pill organizer only if you can keep it dry and at room temperature.
• Do not store in a car or checked baggage where temperatures can vary.

Benefits and Savings

Larotrectinib vitrackvi offers a tumor‑agnostic option guided by a genetic driver, not by tumor site. In clinical studies, many patients experienced meaningful tumor shrinkage, and responses were seen across dozens of tumor types. Oral dosing avoids clinic infusions and helps maintain daily routines.

Ordering through Youdrugstore can reduce costs versus typical U.S. pharmacy pricing. Many customers see 60–80 % savings depending on strength and package size. We also send reorder reminders so you can plan refills. Multi‑month supplies or bulk promotions can lower the per‑month cost. Our team works with licensed, vetted international partner pharmacies to supply authentic brand medications across a wide range at accessible prices.

Looking for deals? See current vitrackvi sales on our promotions page.

Side Effects and Safety

• Common: fatigue, dizziness, nausea, vomiting, constipation, diarrhea, cough.
• Laboratory changes: elevated liver enzymes (ALT/AST), anemia, neutropenia.
• Neurologic: headache, gait disturbance, paresthesia.
• Musculoskeletal: myalgia or arthralgia.
• Abdominal pain or decreased appetite.

Serious risks include hepatotoxicity, neurologic adverse reactions, and embryo‑fetal toxicity. Clinicians monitor liver function frequently during the first month, then regularly. Report new neurologic symptoms. Use effective contraception during treatment and for the recommended period after the last dose. The medication may interact with CYP3A modifiers; your oncology team may adjust dosing if such agents are required. The Vitrakvi fda approval and current vitrackvi label detail dose modifications and monitoring.

Onset Time

Responses often start early in treatment. In pooled trials, median time to response was around 1–2 months. Some patients notice symptom relief sooner, and others need more time as the dose stabilizes. Imaging schedules vary by tumor type and clinical status. Discuss the response‑assessment plan with the oncology team to align scans with your treatment goals.

Compare With Alternatives

Rozlytrek (entrectinib) is another TRK inhibitor with activity against NTRK gene fusion–positive tumors. It also targets ROS1 and ALK, and has different dosing and interaction considerations. Choice between agents depends on prior therapy, comorbidities, drug interactions, and resistance mutations identified on testing.

For cancers driven by different biomarkers, other targeted drugs or immunotherapy may be used. While not direct substitutes for larotrectinib, we also supply other oncology medicines such as Zytiga® for metastatic prostate cancer and Xospata® for FLT3‑mutated acute myeloid leukemia. Your oncology team will select therapy based on tumor biology and treatment history.

Conventional chemotherapy, surgery, or radiation may be used before, during, or after TRK inhibitor therapy depending on response and clinical needs.

Combination Therapy

• Monotherapy is common for NTRK fusion–positive tumors. Continue until progression or unacceptable toxicity.
• Use with surgery or radiation when local control is planned, timed to minimize interruptions.
• Avoid strong CYP3A inducers; consider dose changes if a strong CYP3A inhibitor is necessary.
• Coordinate supportive care medications for nausea, bowel changes, and sleep as needed.
• If resistance emerges, molecular re‑testing can guide next steps.

Patient Suitability and Cost-Saving Tips

Candidates include adults and pediatric patients with unresectable or metastatic solid tumors that test positive for an NTRK gene fusion and lack satisfactory alternatives. Patients without NTRK fusions are not candidates. Confirm fusion status with validated testing before starting therapy. The vitrackvi indication applies regardless of tumor origin when criteria are met.

Use caution in hepatic impairment. Prescribers may reduce the starting dose in moderate or severe hepatic impairment and monitor closely. Dizziness and fatigue can affect activities; use care when driving or operating machinery. Avoid strong CYP3A inducers such as certain antiepileptics or rifampin. Grapefruit products can affect metabolism and are generally avoided. Pregnancy and breastfeeding are not recommended during therapy; contraception is advised.

To manage costs, consider a longer supply when appropriate. A 2–3 month fill can lower per‑month costs and reduce shipping fees. Set up reorder reminders so you do not run out. If you compare vitrackvi cost across pharmacies, note the strength, form (capsules vs solution), and quantity, since these change the final total. Contact us if you need help aligning your prescription with available package sizes.

You can browse related conditions in our Cancer section to see other treatments and supportive care options.

Authoritative Sources

Vitrakvi HCP site (mechanism, dosing, safety)

FDA Drugs@FDA: Vitrakvi (larotrectinib) application and labeling

Health Canada Drug Product Database: product monograph access

Order Vitrakvi® from Youdrugstore: add to cart, upload your prescription, and we ship with prompt, express shipping.

This material is educational and does not replace advice from your healthcare professional. Always follow your prescriber’s directions and your medication guide.